Skip to main content

Table 1 Baseline characteristics and mortality before and after matching in SPH1

From: Vasopressin versus norepinephrine in septic shock: a propensity score matched efficiency retrospective cohort study in the VASST coordinating center hospital

Variable Norepinephrine Vasopressin p
Baseline characteristics before matching of norepinephrine- vs. vasopressin-treated patients in SPH1
 Age (years), X ± SD 60.7 ± 16.2 56.1 ± 15.7 < 0.001
 APACHE II, X ± SD 25.6 ± 8.0 28.8 ± 8.9 < 0.001
 Gender (% male) 61.8 73.3 0.007
 Surgical (%) 39.2 35.2 0.146
 Respiratory (%) 88.3 92.1 0.17
 Renal (%) 68.1 81.2 < 0.001
 Coagulation (%) 23.3 36.4 < 0.001
 Hepatic (%) 14.3 22.4 0.013
 Neurological (%) 64.7 79.4 < 0.001
 Ventilated (%) 92.7 89.1 0.142
 Any chronic disease (%) 44.8 55.8 0.013
 Norepinephrine dose (ug/min) 13.2 ± 14.8 21.4 ± 21.7 < 0.001
Baseline characteristics after matching of norepinephrine- vs. vasopressin-treated patients in SPH1
 Age (years), X ± SD 57.1 ± 15.1 56.4 ± 15.4 0.65
 APACHE II, X ± SD 28.1 ± 8.3 28.4 ± 8.4 0.782
 Gender (% male) 67.1 72.8 0.27
 Surgical (%) 34.8 34.8 1
 Respiratory (%) 93.0 91.8 0.671
 Renal (%) 74.7 81.0 0.176
 Coagulation (%) 28.5 36.1 0.149
 Hepatic (%) 18.4 22.2 0.401
 Neurological (%) 69.0 78.5 0.055
 Ventilated (%) 94.3 89.2 0.101
 Any chronic disease (%) 51.9 54.4 0.652
 Norepinephrine dose (ug/min) 15.9 ± 16.7 19.8 ± 18.9 0.139
Mortality of norepinephrine- vs. vasopressin-treated patients in SPH1
 28-day mortality (%) 46.2 60.8 0.009